Anti-Cytokeratin 10抗体[RKSE60] (ab9025)
Key features and details
- Mouse monoclonal [RKSE60] to Cytokeratin 10
- Suitable for: IHC-Fr, ICC/IF
- Reacts with: Pig, Zebrafish
- Isotype: IgG1
概述
-
产品名称
Anti-Cytokeratin 10抗体[RKSE60]
参阅全部 Cytokeratin 10 一抗 -
描述
小鼠单克隆抗体[RKSE60] to Cytokeratin 10 -
宿主
Mouse -
特异性
This antibody reacts exclusively with cytokeratin 10 which is present in keratinizing stratified epithelia and in differentiated areas of highly differentiated squamous cell carcinomas -
经测试应用
适用于: IHC-Fr, ICC/IFmore details -
种属反应性
与反应: Pig, Zebrafish -
免疫原
Full length native protein (purified) corresponding to Human Cytokeratin 10. Cytokeratins from the human epidermis.
-
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
Preservative: 0.09% Sodium azide
Constituent: PBS -
Concentration information loading...
-
纯度
Protein G purified -
克隆
单克隆 -
克隆编号
RKSE60 -
骨髓瘤
Sp2/0 -
同种型
IgG1 -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
应用
应用 | Ab评论 | 说明 |
---|---|---|
IHC-Fr | (2) |
Use at an assay dependent concentration.
|
ICC/IF |
Use at an assay dependent concentration.
|
说明 |
---|
IHC-Fr
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
靶标
-
组织特异性
Seen in all suprabasal cell layers including stratum corneum. -
疾病相关
Defects in KRT10 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
Defects in KRT10 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months. -
序列相似性
Belongs to the intermediate filament family. - Information by UniProt
-
别名
- BCIE antibody
- BIE antibody
- CK 10 antibody
see all
图片
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (28)
ab9025 被引用在 28 文献中.
- Morin S et al. Eicosapentaenoic Acid Influences the Lipid Profile of an In Vitro Psoriatic Skin Model Produced with T Cells. Biomolecules 13:N/A (2023). PubMed: 37759812
- Kitazawa K et al. Gene expression signatures of human senescent corneal and conjunctival epithelial cells. Aging (Albany NY) 15:9238-9249 (2023). PubMed: 37770232
- Henriet E et al. Targeting TGF-β1/miR-21 Pathway in Keratinocytes Reveals Protective Effects of Silymarin on Imiquimod-Induced Psoriasis Mouse Model. JID Innov 3:100175 (2023). PubMed: 36968096
- Li J et al. CDK12 Is Necessary to Promote Epidermal Differentiation Through Transcription Elongation. Stem Cells 40:435-445 (2022). PubMed: 35325240
- Erratico S et al. Effective high-throughput isolation of enriched platelets and circulating pro-angiogenic cells to accelerate skin-wound healing. Cell Mol Life Sci 79:259 (2022). PubMed: 35474498